Navigation Links
UK's 1st Total Artificial Heart Patient Discharged Home Using Freedom® Portable Driver
Date:8/10/2011

TUCSON, Ariz., Aug. 10, 2011 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that on Aug. 2, Papworth Hospital in Cambridge discharged the United Kingdom's first Total Artificial Heart patient to wait for a matching donor heart at home with his wife and 5-year-old son using the Freedom® portable driver.

(Photo:  http://photos.prnewswire.com/prnh/20110810/LA50030-a)

(Photo:  http://photos.prnewswire.com/prnh/20110810/LA50030-b)

"Two years ago I was cycling nine miles to work and nine miles back every day, but by the time I was admitted to hospital, I was struggling to walk even a few yards," said Total Artificial Heart patient Matthew Green. "I am really excited about going home and just being able to do the everyday things that I haven't been able to do for such a long time, such as playing in the garden with my son and cooking a meal for my family."

Mr. Green, 40, suffered from arrhythmogenic right ventricular cardiomyopathy (ARVC), a heart muscle disease that results in arrhythmia, heart failure and sudden death. His health had been declining over recent years with his only available option being a heart transplant.

"Matthew's condition was deteriorating rapidly and we discussed with him the possibility of receiving this device, because without it he may not have survived the wait until a suitable donor heart could be found for him," said Mr. Steven Tsui, Consultant Cardiothoracic Surgeon and Director of the Transplant Service. "The operation went extremely well and Matthew has made an excellent recovery."

On June 9, Mr. Green became the first patient in the United Kingdom to receive SynCardia's Total Artificial Heart. Two months later, he was discharged from the hospital using the Freedom portable driver. Weighing 13.5 pounds, including two onboard lithium-ion batteries, the Freedom driver is the world's first wearable portable driver designed to power SynCardia's Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Papworth Hospital is the first and only hospital in the UK certified to implant SynCardia's Total Artificial Heart. Papworth performed the UK's first heart transplant in 1979 and has been using mechanical devices to support patients with end-stage heart failure since the 1980's.

Watch news stories about Papworth's 1st implant

Read press release from Papworth Hospital

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 900 implants account for more than 210 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients." Also in March, the longest running health and wellness series on public television, "Healthy Body, Healthy Mind," produced a 30-minute program featuring SynCardia's Total Artificial Heart. View here

For additional information, please visit: http://www.syncardia.com

or follow SynCardia on Twitter – @SynCardia_News


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
2. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
3. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
4. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
5. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
6. Cleveland Clinic Surgeons Perform Nations First Near-Total Face Transplant
7. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
8. Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research
9. Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling $10.7 Million of Annual Net Revenue
10. Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress
11. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to ... available through Jet.com. , After 25 years of development, the company released its ... quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the family ... is from Southwest Nebraska where she was raised on a farm. As Diane ... is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always been ...
Breaking Medicine News(10 mins):